Volume 24, Issue 2 p. 223-227
Original article

Effect of benzopyranoperidine, a Δ-9-THC congener, on pain

Peter R. Jochimsen M.D.

Peter R. Jochimsen M.D.

The Departments of Surgery and Psychiatry, University of Iowa Hospitals, Iowa City, Iowa

Search for more papers by this author
Richard L. Lawton M.D.

Richard L. Lawton M.D.

The Departments of Surgery and Psychiatry, University of Iowa Hospitals, Iowa City, Iowa

Search for more papers by this author
Kyle VerSteeg M.D.

Kyle VerSteeg M.D.

The Departments of Surgery and Psychiatry, University of Iowa Hospitals, Iowa City, Iowa

Search for more papers by this author
Russell Noyes Jr. M.D.

Russell Noyes Jr. M.D.

The Departments of Surgery and Psychiatry, University of Iowa Hospitals, Iowa City, Iowa

Search for more papers by this author
,
First published: August 1978
Citations: 45
Supported by Grant RR-59 from the General Clinical Research Centers Program, Division of Research Resources, National Institutes of Health and Abbott Laboratories.
Reprint requests to: Dr. Peter R. Jochimsen, Department of Surgery, University of Iowa Hospitals, Iowa City, IA 52242.

Abstract

In a double-blind, 5-way crossover designed study, single doses of placebo, 2 doses of codeine sulfate (60 and 120 mg), and 2 doses of benzopyranoperidine (2 and 4 mg) were administered orally to 35 patients who required analgesics for chronic pain due to malignancies. Benropyranopyridine is an analogue of delta-9-tetrahydrocannabinol and was chosen on the basis of its sedative, hypnotic, and analgesic properties in animals. Pain relief scores indicated a degree of relief of clinical significance witn 120 mg of codeine but no consistent difference between placebo and any other active agent. On the basis of the data, benzopvranoperidine (2 or 4 mg) is not as effective as codeine (120 mg or 60 mg) and no more effective than placebo in relieving pain due to cancer; indeed, pain perception appeared to be augmented by both doses.